Close Menu
    Facebook X (Twitter) Instagram
    TRENDING :
    • Don’t Be Fooled by Elon Musk’s Big Pivot
    • The Nvidia CEO scandal is impacting Asian American women in tech and academia. Here’s how
    • NFL Glance: Your Quick Look at Today’s Games and Standings
    • Bernie Sanders: A Foreign Policy for the Many
    • ‘Worst COP ever’? Climate talks in Turkey are near the finish line and activists are in an uproar
    • Group of 6 Week 12 Picks: Our Favorite Upset Bets
    • Peeping AI agents are ‘hostile to privacy,’ says Meredith Whittaker, so Signal is blocking screenshots
    • Suns, Jazz Look to Steady Footing Before NBA Cup Clash
    Populist Bulletin
    • Home
    • US Politics
    • World Politics
    • Economy
    • Business
    • Headline News
    Populist Bulletin
    Home»Business»Why Novo Nordisk stock fell 7% after a telehealth startup’s announcement
    Business 3 Mins Read

    Why Novo Nordisk stock fell 7% after a telehealth startup’s announcement

    Business 3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email Copy Link
    Follow Us
    Google News Flipboard
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Novo Nordisk’s stock dove 7% on Thursday just after an announcement from a key competitor.

    The drop came just after telehealth company Hims & Hers announced it will offer a new version of the treatment, made from the same active ingredient, semaglutide, for a fraction of Novo Nordisk’s price. The telehealth site will offer the treatment at an introductory price of $49, the announcement said. After the introductory offer ends, patients with a five-month subscription will pay $99 monthly for the treatment. Novo Nordisk sells the weight-loss drug for $149. 

    Hims & Hers had already been offering the treatment in an injectable form, but the oral version is new for the brand. “We’re excited to find ways to continue bringing branded treatments to the platform across specialties. More choice on the platform is the best thing for customers everywhere,” said Hims CEO Andrew Dudum in a statement.

    While the announcement spurred Novo Nordisk’s stock to reach its lowest level since July 2021, it wasn’t the only company that saw its stock slip on Thursday. Eli Lilly’s fell by up to 6.1% on the announcement. Meanwhile, Hims and Hers Health stock surged 19% on Thursday.

    On Wednesday, Novo CFO Karsten Munk Knudsen told Reuters that the company is “frustrated” with “mass marketing” of knock-off versions of the drug which was “unapproved by the FDA.” The CFO warned of unprecedented pricing pressure as competition grows in the weight-loss drug market, added that it’s a challenge to predict “if and when the tide turns” for the brand.

    Per Hims & Hers announcement, the company said that safety is the brand’s “top priority.” It continued, “The Compounded Semaglutide Pill joins a wide range of other weight loss treatments accessible through our platform, all of which meet rigorous clinical standards.”

    “The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework,” the company said in a statement regarding the Hims & Hers announcement. “This is another example of Hims & Hers’ historic behaviour of duping the American public with knock-off GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knock-offs.

    The American Diabetes Association’s Obesity Association recently published new standards of care, which discourage the use of compounded GLP-1s due to safety, quality, and effectiveness concerns. 

    Only Novo Nordisk manufactures an FDA-approved Wegovy pill formulated with SNAC technology, which facilitates semaglutide absorption when administered orally.  The Wegovy pill is available in all doses, in full supply, nationwide in the US. Compounded semaglutide is not approved by the FDA and may contain impurities, unnecessary additives, and untested doses.”

    In November, when the company dropped its prices to fend off competition, Dave Moore, executive vice president of U.S. operations at Novo Nordisk, said, “As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them.”

    Moore continued: “The U.S. healthcare system is complex, with different types of insurance and various ways for patients to obtain their medicines. Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay.”



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    The Nvidia CEO scandal is impacting Asian American women in tech and academia. Here’s how

    November 20, 2026

    ‘Worst COP ever’? Climate talks in Turkey are near the finish line and activists are in an uproar

    November 20, 2026

    Peeping AI agents are ‘hostile to privacy,’ says Meredith Whittaker, so Signal is blocking screenshots

    November 20, 2026
    Top News
    Business 12 Mins Read

    10 Essential CSAT Questions to Practice

    Business 12 Mins Read

    When considering how to improve customer satisfaction, it’s crucial to implement effective CSAT questions in…

    Ready to buy your breakfast with Bitcoin? Square is making it easier

    October 9, 2025

    Louisiana High School Football Top 10 Rankings

    October 1, 2026

    Midland Valley Honors 9/11 Before Stormy Football Showdown

    September 13, 2026
    Top Trending
    US Politics 7 Mins Read

    Don’t Be Fooled by Elon Musk’s Big Pivot

    US Politics 7 Mins Read

    Politics / November 20, 2026 Musk and James Murdoch are touting their…

    Business 6 Mins Read

    The Nvidia CEO scandal is impacting Asian American women in tech and academia. Here’s how

    Business 6 Mins Read

    The reveal earlier this month that billionaire Nvidia CEO Jensen Huang had…

    World Politics 1 Min Read

    NFL Glance: Your Quick Look at Today’s Games and Standings

    World Politics 1 Min Read

    WFMZ’s NFL Glance rounds up the latest league action, giving fans a…

    Categories
    • Business
    • Economy
    • Headline News
    • Top News
    • US Politics
    • World Politics
    About us

    The Populist Bulletin was founded with a fervent commitment to inform, inspire, empower and spark meaningful conversations about the economy, business, politics, government accountability, globalization, and the preservation of American cultural heritage.

    We are devoted to delivering straightforward, unfiltered, compelling, relatable stories that resonate with the majority of the American public, while boldly challenging false mainstream narratives that seem to only serve entrenched elitists, and foreign interests.

    Top Picks

    Don’t Be Fooled by Elon Musk’s Big Pivot

    November 20, 2026

    The Nvidia CEO scandal is impacting Asian American women in tech and academia. Here’s how

    November 20, 2026

    NFL Glance: Your Quick Look at Today’s Games and Standings

    November 20, 2026
    Categories
    • Business
    • Economy
    • Headline News
    • Top News
    • US Politics
    • World Politics
    Copyright © 2025 Populist Bulletin. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.